de la Fuente S, Citores M J, Baños I, Duca A, Cuervas-Mons V
Unidad de Trasplante Hepático, Servicio de Medicina Interna, Hospital Universitario Puerta de Hierro-Majadahonda, Majadahonda, Madrid, Spain.
Unidad de Trasplante Hepático, Servicio de Medicina Interna, Hospital Universitario Puerta de Hierro-Majadahonda, Majadahonda, Madrid, Spain.
Transplant Proc. 2014 Nov;46(9):3111-3. doi: 10.1016/j.transproceed.2014.10.003.
Liver transplantation (LT) in adult patients is associated with a higher incidence of cardiovascular risk factors (CVRF), chronic kidney disease (CKD), and cardiovascular disease mortality than the general population. Available information about these problems in adult patients with LT from a pediatric age is limited. The aim of this study was to analyze the incidence of CVRF, risk of developing CKD, and risk of 10-year coronary event in adult patients who received LT in childhood.
Thirty adult patients (11 female, 19 male; mean age, 29.3 years) who underwent LT in childhood were analyzed, and CVRF, estimated glomerular filtration rate, and current immunosuppressive regimen were recordered. The risk of 10-year coronary event was calculated with the use of validated equations (Framingham and Regicor) and compared with the estimated risk in the general population.
None of the patients had CVRF before LT, except 1 patient who received a transplant because of familial hypercholesterolemia. Median age of patients at the time of study was 28.6 years (range, 19.3-43.1 y), and mean follow-up after LT was 17.83 ± 5.21 years. Twenty-nine patients (96.7%) were receiving a calcineurin inhibitor (69% tacrolimus, 31% cyclosporine), along with steroids in 13 of them. The average CVRF per patient was 2, and 11 patients (43.33%) had ≥3. Thirteen patients (43.33%) had CKD. The estimated risk of developing a coronary event at 10 years according to the Framingham score was 3%, higher than expected in the general population of same age and sex. With the use of the Regicor equation, adapted to the Spanish population, the estimated cardiovascular risk was 1.6%, corresponding to Spanish men without CVRF aged 50-55 years. None of the patients had cardiovascular events during the follow-up.
Our data show a high incidence of CVRF and CKD in young adults who received LT in childhood, resulting in an increased risk of cardiovascular disease.
与普通人群相比,成年患者肝移植(LT)后心血管危险因素(CVRF)、慢性肾脏病(CKD)的发生率以及心血管疾病死亡率更高。关于儿童期接受肝移植的成年患者这些问题的现有信息有限。本研究的目的是分析儿童期接受肝移植的成年患者中CVRF的发生率、发生CKD的风险以及10年冠状动脉事件风险。
分析30例儿童期接受肝移植的成年患者(11例女性,19例男性;平均年龄29.3岁),记录其CVRF、估计肾小球滤过率及当前免疫抑制方案。使用经过验证的方程(弗明汉方程和雷希科尔方程)计算10年冠状动脉事件风险,并与普通人群的估计风险进行比较。
除1例因家族性高胆固醇血症接受移植的患者外,移植前无患者存在CVRF。研究时患者的中位年龄为28.6岁(范围19.3 - 43.1岁),肝移植后的平均随访时间为17.83±5.21年。29例患者(96.7%)接受钙调神经磷酸酶抑制剂治疗(69%使用他克莫司,31%使用环孢素),其中13例同时使用类固醇。每位患者的平均CVRF为2个,11例患者(43.33%)有≥3个。13例患者(43.33%)患有CKD。根据弗明汉评分,10年发生冠状动脉事件的估计风险为3%,高于同年龄和性别的普通人群预期。使用适用于西班牙人群的雷希科尔方程,估计心血管风险为1.6%,相当于50 - 55岁无CVRF的西班牙男性。随访期间无患者发生心血管事件。
我们的数据显示,儿童期接受肝移植的年轻成年人中CVRF和CKD的发生率较高,导致心血管疾病风险增加。